| 6.865 0.125 (1.85%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.9 | 1-year : | 10.96 |
| Resists | First : | 7.62 | Second : | 9.39 |
| Pivot price | 7.47 |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 6.41 |
MA(20) : | 7.15  |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 36.5 |
D(3) : | 29.3 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 20.71 | Low : | 4.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TELO ] has closed above bottom band by 34.9%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 6.87 - 6.9 | 6.9 - 6.93 |
| Low: | 5.83 - 5.86 | 5.86 - 5.89 |
| Close: | 6.8 - 6.86 | 6.86 - 6.92 |
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Fri, 12 Apr 2024
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A ... - Marketscreener.com
Tue, 26 Mar 2024
Telomir-1 partners with Argenta for canine osteoarthritis study - Investing.com Nigeria
Tue, 26 Mar 2024
Telomir Pharmaceuticals announces collaboration with Argenta - TipRanks.com - TipRanks
Thu, 07 Mar 2024
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ... - Yahoo Finance
Mon, 04 Mar 2024
Eyeing AI Tech Stocks: (Nasdaq: KSCP) (NYSE: PATH) (CBOE: VHAI) (NYSE: SRYA) - Investorideas.com newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.654e+007 (%) |
| Held by Institutions | 42.4 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -102.2 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 15710 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|